When Mark and I co-founded BigHat Biosciences in 2019, we had a bold vision: combine machine learning and synthetic biology to revolutionize therapeutic antibody design. We believed that by leveraging AI, we could dramatically improve the speed, precision, and scalability of drug discovery—ultimately bringing better therapies to patients, faster.

Over the past five years, we’ve turned that vision into reality. BigHat now operates the fastest, highest-scale antibody design system in the world, generating thousands of unique designs per week. Our ML-powered platform has become a cornerstone of our success, enabling partnerships with Amgen, Merck, AbbVie, Johnson & Johnson, and others, while tackling molecular engineering challenges once thought impossible to unlock new ways of treating patients.

Internally, we’ve built a world-class cross-disciplinary team and advanced a pipeline of preclinical assets across oncology and immunology, including antibody-drug conjugates (ADCs) and T-cell engagers. Some of our most promising programs have already moved into manufacturing, with clinical trials set to begin in 2026. We are well-positioned to transition to a clinical stage company.

Now, as BigHat enters that next phase of growth, I am honored to step into the role of CEO.

Looking Ahead

BigHat has been built on a strong foundation of innovation, collaboration, and a shared vision for transforming therapeutic discovery. Mark has been an invaluable co-founder, leader, and partner in shaping the company into what it is today. His passion and drive have helped establish the platform, team, and strategy that position us for long-term success.

For the past five years, I’ve had the privilege of working alongside Mark to build BigHat—from advancing our platform to driving our lead therapeutic programs. Together, we have laid the groundwork for the company’s next phase, and I am deeply committed to carrying that vision forward. On behalf of our entire team, I want to extend my immense gratitude and appreciation to Mark for serving as BigHat’s first CEO. I’m looking forward to working with you as an ongoing advisor.

We are at a pivotal moment, and I am more excited than ever about where BigHat is headed. With our team’s expertise and dedication, I have full confidence in our ability to execute on our next chapter and continue making a meaningful impact for patients.

What’s Next for BigHat?

As CEO, my focus is clear:

• Advancing our pipeline and preparing for our first clinical trials in 2026.
• Strengthening our partnerships to drive impact across the biotech and pharma landscape.
• Expanding our leadership team with top clinical talent to complement our preclinical expertise.
• Staying true to BigHat’s mission—bringing breakthrough therapies to patients faster and more efficiently than ever before.

With a strong foundation, an exceptional team, and a healthy balance sheet, we are poised to lead the next era of ML-powered therapeutics.

To our employees, partners, investors, and broader BigHat community—thank you for your trust and support. I am incredibly excited for what we will accomplish together.

- Peyton Greenside
CEO, BigHat Biosciences

‍